Researchers discovered that pregnancy-related hormones significantly increase concentrations of CYP3A4, a key enzyme in drug metabolism. This finding has significant implications for managing medications during pregnancy and may provide insights into the development of new ADME-tox models.
A new assay using HEPATOPAC model identifies drugs with high DILI risk, showing high sensitivity and specificity. BioIVT's advanced in vitro liver model provides a promising solution for preclinical DILI risk assessment.
Researchers found that HIV integrase inhibitor dolutegravir is not a clinical inhibitor of folate transport pathways, reducing concerns about its impact on maternal and fetal health. The study's results suggest that these drugs may be safer for pregnant women than previously thought.
A new study investigates potential botanical-drug interactions (BDIs) with Boswellia serrata extract, a widely used anti-inflammatory supplement. The study compared two in vitro methods and found that the sandwich-cultured human hepatocyte model is a more accurate predictor of BDIs.
Certara has published four peer-reviewed papers on MIPD, outlining the vision and practical path for making individualized dosing a reality. MIPD uses computer modeling to predict optimal drug doses for patients based on their unique characteristics, especially those in vulnerable populations.
Researchers discovered a link between BSEP inhibition and FXR activation, explaining the weak concordance between BSEP inhibition potency and cholestatic DILI incidence. The C-DILI assay has been shown to have high in vitro-in vivo correlation among compounds known to have a risk of DILI.
Researchers use viral kinetic models to increase understanding of influenza biology and antiviral pharmacology, identifying sources of variation between individuals. These models have been used to support dose optimization and clinical development of potential influenza therapies.
A mathematical model of tumor growth inhibition predicts treatment effect with bevacizumab for patients with metastatic colorectal cancer. The best metric for predicting overall survival was time to tumor growth, which worked equally well in Western and Chinese patients.